1. Roche s Stock May Have Been Down, But The Company s Business Has Strong Outlook http://www.trefis.com/stock/rhhby/articles/335839/roches-stock-may-have-been-down-but-the-companys-business-has-strong-outlook/2016-02-02 by Trefis Team $RHHBY $MRK $BMY

  2. Pharma Stocks Are Down But There Is Still Value To Be Unlocked http://www.trefis.com/stock/rhhby/articles/331431/pharma-stocks-are-down-but-there-is-still-value-to-be-unlocked/2016-01-13 by Trefis Team $RHHBY $BMY $PFE

  3. By What Percentage Did Bristol-Myers Squibb s Revenue & EBITDA Grow In The Last 5 Y... http://www.trefis.com/stock/bmy/articles/328934/by-what-percentage-did-bristol-myers-squibbs-revenue-ebitda-grow-in-the-last-5-years/2015-12-30 by Trefis Team $BMY $JNJ $RHHBY

  4. What’s Bristol-Myers Squibb’s Fundamental Value Based On Expected 2015 Results? http://www.trefis.com/stock/bmy/articles/328726/whats-bristol-myers-squibbs-fundamental-value-based-on-expected-2015-results/2015-12-30 by Trefis Team $BMY $RHHBY $MRK

  5. What s Pfizer s Revenue And Earnings Breakdown? http://www.trefis.com/stock/pfe/articles/327818/whats-pfizers-revenue-and-earnings-breakdown/2015-12-23 by Trefis Team $PFE $JNJ $RHHBY

  6. By What Percentage Can Pfizer s Revenue & EBITDA Grow In The Next 3 Years? http://www.trefis.com/stock/pfe/articles/328242/by-what-percentage-can-pfizers-revenue-ebitda-grow-in-the-next-3-years/2015-12-23 by Trefis Team $PFE $RHHBY $JNJ

  7. By What Percentage Did Pfizer s Revenue & EBITDA Decline In The Last 5 Years? http://www.trefis.com/stock/pfe/articles/327825/by-what-percentage-did-pfizers-revenue-ebitda-decline-in-the-last-5-years/2015-12-23 by Trefis Team $PFE $MRK $RHHBY

  8. Why J&J s Stock Unlikely To Move Significantly In The Near Term? http://www.trefis.com/stock/jnj/articles/327485/why-jjs-stock-unlikely-to-move-significantly-in-the-near-term/2015-12-22 by Trefis Team $JNJ $PFE $RHHBY

  9. Why Merck’s Cancer Drug Keytruda Can Be Key To Its Long Term Growth? http://www.trefis.com/stock/mrk/articles/327294/why-mercks-cancer-drug-keytruda-can-be-key-to-its-long-term-growth/2015-12-18 by Trefis Team $MRK $PFE $RHHBY

  10. If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful E... http://www.trefis.com/stock/jnj/articles/326839/if-remicade-biosimilar-hits-the-u-s-market-in-2017-does-jj-face-any-meaningful-eps-decline/2015-12-17 by Trefis Team $JNJ $RHHBY $MRK

  11. How Much Revenues Can J&J’s Phase 3 Pipeline Add By 2020? http://www.trefis.com/stock/jnj/articles/326789/how-much-revenues-can-jjs-phase-3-pipeline-add-by-2020/2015-12-17 by Trefis Team $JNJ $PFE $RHHBY

  12. By What Percentage Can Merck s Revenue Grow Over The Next 3 Years? http://www.trefis.com/stock/mrk/articles/327052/by-what-percentage-can-mercks-revenue-grow-over-the-next-3-years/2015-12-16 by Trefis Team $MRK $PFE $RHHBY

  13. What s Merck s Revenue And Earnings Breakdown In Terms Of Therapeutic Areas? http://www.trefis.com/stock/mrk/articles/326862/whats-mercks-revenue-and-earnings-breakdown-in-terms-of-therapeutic-areas/2015-12-16 by Trefis Team $MRK $RHHBY $BMY

  14. What Led To Nearly 15% Decline In Merck’s Revenues & EBITDA In The Last 5 Years? http://www.trefis.com/stock/mrk/articles/326881/what-led-to-nearly-15-decline-in-mercks-revenues-ebitda-in-the-last-5-years/2015-12-16 by Trefis Team $MRK $BMY $RHHBY

  15. What s Merck s Fundamental Value Based On Expected 2015 Results? http://www.trefis.com/stock/mrk/articles/326865/whats-mercks-fundamental-value-based-on-expected-2015-results/2015-12-16 by Trefis Team $MRK $PFE $RHHBY

  16. Looking At M&A History, What Metrics Suggest That Pfizer Has Been Conservative Whi... http://www.trefis.com/stock/pfe/articles/326440/looking-at-ma-history-what-metrics-suggest-that-pfizer-has-been-conservative-while-engineering-allergan-deal/2015-12-14 by Trefis Team $PFE $RHHBY $JNJ

  17. How Much Additional Synergies Does Pfizer Require To Justify Premium Paid For Alle... http://www.trefis.com/stock/pfe/articles/326432/how-much-additional-synergies-does-pfizer-require-to-justify-premium-paid-for-allergan/2015-12-14 by Trefis Team $PFE $RHHBY $MRK

  18. By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years? http://www.trefis.com/stock/jnj/articles/325820/by-how-much-can-jjs-revenue-and-ebitda-grow-over-the-next-3-years/2015-12-10 by Trefis Team $JNJ $RHHBY $BMY

  19. By What Percentage Did J&J s Revenue & EBITDA Grow In The Last 5 Years? http://www.trefis.com/stock/jnj/articles/325801/by-what-percentage-did-jjs-revenue-ebitda-grow-in-the-last-5-years/2015-12-10 by Trefis Team $JNJ $RHHBY $PFE

  20. What Can Move Roche’s Stock By 40% Next Year? http://www.trefis.com/stock/rhhby/articles/325640/what-can-move-roches-stock-by-40-next-year/2015-12-09 by Trefis Team $RHHBY $BMY $JNJ

  21. How Much Revenues Can Roche’s Phase 3 Pipeline Add In The Next 5 Years? http://www.trefis.com/stock/rhhby/articles/325621/how-much-revenues-can-roches-phase-3-pipeline-add-in-the-next-5-years/2015-12-09 by Trefis Team $RHHBY $PFE $MRK

  22. How Has Roche’s Revenue & Earnings Composition Changed In The Last 5 Years? http://www.trefis.com/stock/rhhby/articles/325528/how-has-roches-revenue-earnings-composition-changed-in-the-last-5-years/2015-12-09 by Trefis Team $RHHBY $BMY $MRK

  23. What s Roche s Fundamental Value Based On Expected 2015 Results? http://www.trefis.com/stock/rhhby/articles/325525/whats-roches-fundamental-value-based-on-expected-2015-results/2015-12-09 by Trefis Team $RHHBY $JNJ $PFE

  24. By How Much Will Roche’s Revenues And Earnings Grow In The Next 3 Years? http://www.trefis.com/stock/rhhby/articles/325560/by-how-much-will-roches-revenues-and-earnings-grow-in-the-next-3-years/2015-12-09 by Trefis Team $RHHBY $PFE $MRK

  25. How Can Roche Get 25% Boost In Revenues In 5 Years? http://www.trefis.com/stock/rhhby/articles/324389/how-can-roche-get-25-boost-in-revenues-in-5-years/2015-11-27 by Trefis Team $RHHBY $MRK $PFE